Poxel S.A. (0RA2.L)
| Previous close | 1.6000 |
| Open | 5.6442 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.6000 - 1.6000 |
| 52-week range | 0.3530 - 1.6000 |
| Volume | |
| Avg. volume | 3,695 |
| Market cap | 394,955 |
| Beta (5Y monthly) | 1.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WirePoxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023
LYON, France, November 08, 2023--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2023.
Business WirePoxel Announces its Participation at Upcoming Investor Conferences
LYON, France, October 12, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at two upcoming investor conferences.
Business WirePoxel Announces its Participation at Upcoming Scientific Conference
LYON, France, October 02, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.
